The Relation Between the Prognosis of Subthalamic Nucleus Deep Brain Stimulation Surgery by Microlesion Effect and Electrode Position
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: the score of UPDRS item, the score of UPDRS item, the score of UPDRS item, the score of UPDRS item.
- Who it may be relevant to
- Registry conditions: Parkinson's Disease (PD), Deep Brain Stimulation. Basic parameters: 18 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
BACKGROUND: Parkinson's disease (PD) is a common movement disorder whose main symptoms include resting tremor, rigidity and bradykinesia. Deep Brain Stimulation (DBS) has become one of the most effective treatments for PD by implanting electrodes in specific deep brain nuclei to alleviate motor symptoms in PD patients. During the implantation of electrodes in the DBS procedure, small lesions produced are known as the Microlesion Effect, which disappears within a short period. The MLE efficacy is positively correlated with the overall efficacy of DBS, but whether the MLE efficacy is affected by the symptoms has not yet been investigated, and a large-sample study is needed to further validate this. This study aims to examine the relationship between electrode implantation location and the prediction of MLE efficacy produced by STN-DBS surgery in PD patients, assess the correlation between electrode implantation location and DBS efficacy in PD patients, and analyze the role of brain networks in the process. The study will also analyze the relationship between micro-destructive effects and long-term DBS efficacy, providing more effective efficacy prediction and a more accurate selection of electrode implantation locations for DBS treatment in PD patients. This study will guide the clinical practice of DBS treatment in PD patients and provide an important reference for future research in related fields. Object: Primary Parkinson's Disease patients between the ages of 18 and 75 years who meet STN-DBS surgery criteria Aim: To observe the relationship between predicted efficacy and implantation location of STN-DBS for MLE in PD surgery
Interventions
- Other the score of UPDRS item
The score of MDS-UPDRS item 3.1 greater or equal to 2 during the drug-off period at baseline - Other the score of UPDRS item
The score of MDS-UPDRS item 3.3 greater or equal to 2 during the drug-off period at baseline - Other the score of UPDRS item
The score of MDS-UPDRS item 3.10 greater or equal to 2 during the drug-off period at baseline - Other the score of UPDRS item
Any one of the MDS UPDRS 3.15-3.17 scores greater or equal to 2 during the drug-off period at baseline - Other the score of UPDRS item
Sum of MDS UPDRS 4.1-4.2 scores greater than or equal to 3
Primary outcome measures
- Comparing MLE and DBS efficacy [Time frame: From baseline to 24 hours, 48 hours, 7 days ,6 months,one year after surgery]
Secondary outcome measures (3)
- Comparison of the efficacy of electrode positions in relation to different positions of the nucleus pulposus [Time frame: From baseline to 24 hours, 48 hours, 7 days ,6 months,one year after surgery]
- Compare short-term postoperative efficacy with postoperative efficacy after start-up [Time frame: From baseline to 24 hours, 48 hours, 7 days ,6 months,one year after surgery]
- Compare the difference in the rate of improvement in MDS UPDRS-III scores within the postoperative pre-opening period [Time frame: From baseline to 24 hours, 48 hours, 7 days ,6 months,one year after surgery]
Eligibility criteria
Inclusion criteria
- Idiopathic Parkinson Disease
- Age from 18 to 80 years old
- Performed bilateral STN-DBS
Exclusion criteria
- Does not meet STN-DBS surgical criteria
- Patients with severely offset electrode implantation position (imaging)
- Not fulfilling the criteria for an arbitrary cohort under exposure conditions;
- Patients who are unable to voluntarily sign an informed consent form;
- Patients who do not agree to cooperate with follow-up visits
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- The Second Affiliated Hospital of Nanchang University — Nanchang
Publications
- Liang L, Zhao J, Wang H, Chen L, Shi Q, Yang X, Ma H, Zhu Y, Li Z, Huang W. The microlesion effect is associated with global cognitive impairment and predicts motor outcomes after subthalamic deep brain stimulation in Parkinson's disease. J Neurol. 2025 Oct 18;272(11):708. doi: 10.1007/s00415-025-13443-z. PMID 41109904
Identifiers
NCT: NCT06685510 · LC23DBSIIT-HW02